212 related articles for article (PubMed ID: 21110315)
1. The growing diversity and spectrum of action of myeloid-derived suppressor cells.
Mantovani A
Eur J Immunol; 2010 Dec; 40(12):3317-20. PubMed ID: 21110315
[TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cell role in tumor-related inflammation.
Dolcetti L; Marigo I; Mantelli B; Peranzoni E; Zanovello P; Bronte V
Cancer Lett; 2008 Aug; 267(2):216-25. PubMed ID: 18433992
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.
Sinha P; Clements VK; Fulton AM; Ostrand-Rosenberg S
Cancer Res; 2007 May; 67(9):4507-13. PubMed ID: 17483367
[TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cell activation by combined LPS and IFN-gamma treatment impairs DC development.
Greifenberg V; Ribechini E; Rössner S; Lutz MB
Eur J Immunol; 2009 Oct; 39(10):2865-76. PubMed ID: 19637228
[TBL] [Abstract][Full Text] [Related]
5. IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.
Elkabets M; Ribeiro VS; Dinarello CA; Ostrand-Rosenberg S; Di Santo JP; Apte RN; Vosshenrich CA
Eur J Immunol; 2010 Dec; 40(12):3347-57. PubMed ID: 21110318
[TBL] [Abstract][Full Text] [Related]
6. Antigen specificity of immune suppression by myeloid-derived suppressor cells.
Solito S; Bronte V; Mandruzzato S
J Leukoc Biol; 2011 Jul; 90(1):31-6. PubMed ID: 21486906
[TBL] [Abstract][Full Text] [Related]
7. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L; Peranzoni E; Ugel S; Marigo I; Fernandez Gomez A; Mesa C; Geilich M; Winkels G; Traggiai E; Casati A; Grassi F; Bronte V
Eur J Immunol; 2010 Jan; 40(1):22-35. PubMed ID: 19941314
[TBL] [Abstract][Full Text] [Related]
8. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2.
Zhang Y; Liu Q; Zhang M; Yu Y; Liu X; Cao X
J Immunol; 2009 Mar; 182(6):3801-8. PubMed ID: 19265159
[TBL] [Abstract][Full Text] [Related]
9. Myeloid-derived suppressor cell heterogeneity and subset definition.
Peranzoni E; Zilio S; Marigo I; Dolcetti L; Zanovello P; Mandruzzato S; Bronte V
Curr Opin Immunol; 2010 Apr; 22(2):238-44. PubMed ID: 20171075
[TBL] [Abstract][Full Text] [Related]
10. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients.
Mandruzzato S; Solito S; Falisi E; Francescato S; Chiarion-Sileni V; Mocellin S; Zanon A; Rossi CR; Nitti D; Bronte V; Zanovello P
J Immunol; 2009 May; 182(10):6562-8. PubMed ID: 19414811
[TBL] [Abstract][Full Text] [Related]
11. On the armament and appearances of human myeloid-derived suppressor cells.
Poschke I; Kiessling R
Clin Immunol; 2012 Sep; 144(3):250-68. PubMed ID: 22858650
[TBL] [Abstract][Full Text] [Related]
12. Myeloid derived suppressor cells in transplantation.
Lees JR; Azimzadeh AM; Bromberg JS
Curr Opin Immunol; 2011 Oct; 23(5):692-7. PubMed ID: 21802931
[TBL] [Abstract][Full Text] [Related]
13. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy.
Talmadge JE
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5243-8. PubMed ID: 17875751
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of an IL-1alpha vaccine depends on IL-1RI availability and concomitant myeloid-derived suppressor cell reduction.
Weiss T; Vitacolonna M; Zöller M
J Immunother; 2009; 32(6):552-64. PubMed ID: 19483654
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells.
Nefedova Y; Fishman M; Sherman S; Wang X; Beg AA; Gabrilovich DI
Cancer Res; 2007 Nov; 67(22):11021-8. PubMed ID: 18006848
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-derived suppressor cells: characterization and expansion in models of endotoxemia and transplantation.
Van Rompaey N; Le Moine A
Methods Mol Biol; 2011; 677():169-80. PubMed ID: 20941610
[TBL] [Abstract][Full Text] [Related]
17. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells.
Medina-Echeverz J; Fioravanti J; Zabala M; Ardaiz N; Prieto J; Berraondo P
J Immunol; 2011 Jan; 186(2):807-15. PubMed ID: 21148040
[TBL] [Abstract][Full Text] [Related]
18. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.
Ochoa AC; Zea AH; Hernandez C; Rodriguez PC
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):721s-726s. PubMed ID: 17255300
[TBL] [Abstract][Full Text] [Related]
19. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
Marigo I; Dolcetti L; Serafini P; Zanovello P; Bronte V
Immunol Rev; 2008 Apr; 222():162-79. PubMed ID: 18364001
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-derived suppressor cells in cancer patients: a clinical perspective.
Montero AJ; Diaz-Montero CM; Kyriakopoulos CE; Bronte V; Mandruzzato S
J Immunother; 2012; 35(2):107-15. PubMed ID: 22306898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
